SCHEDULE: Beryl Capital Exits Y-mAbs Therapeutics Stake

Beryl Capital Management and its affiliates have reported a complete divestment of their beneficial ownership in Y-mAbs Therapeutics, Inc., reducing their stake to 0%.

Summary

• Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP, and David A. Witkin are the reporting persons in this Schedule 13G Amendment No. 1.
• The filing indicates that as of September 30, 2025, all reporting persons beneficially own 0 shares of Y-mAbs Therapeutics, Inc. Common Stock.
• This represents 0% of the class of securities, signifying a complete divestment of their previous stake.
• The reporting persons disclaim beneficial ownership of Common Stock except to the extent of their pecuniary interest therein.

Sentiment

Score: 5

Explanation: The filing is a factual report of a change in beneficial ownership, indicating a complete divestment by the reporting entities. Without further context on the reasons for divestment, the sentiment is neutral regarding the company's operational performance, though the market may interpret the divestment as a negative signal.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders of Y-mAbs Therapeutics, Inc. may perceive the complete divestment by Beryl Capital Management and its affiliates as a potential signal of diminished confidence or a strategic shift by a significant institutional investor, which could influence market sentiment.

Key Dates

Recommendation

The filing indicates a complete divestment by Beryl Capital Management and its affiliates, reducing their stake in Y-mAbs Therapeutics, Inc. to zero. While this is a factual report of an ownership change, a seasoned investor would interpret a major institutional investor reducing its stake to zero as a potential signal of diminished confidence or a strategic shift. Further investigation into Y-mAbs Therapeutics, Inc.'s fundamentals and the specific reasons for this divestment would be crucial before making a definitive buy or sell decision. Therefore, a 'hold' recommendation is appropriate, pending further analysis of the underlying business and market conditions.

Keywords

Y-mAbs Therapeutics, Beryl Capital Management, Schedule 13G, beneficial ownership, common stock, institutional investor, equity divestment